1. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months) 
Claudia Felipe, PhD, Helio Tedesco-Silva, MD, Alexandra Ferreira Brigido, MD, Adrieli Bessa, PharmD, Priscila Ruppel, PharmD, Liliane Hiramoto, PharmD, Mayara de Paula, PharmD, Marina Cristelli, PharmD, Suelen Stopa, MD, Juliana Mansur, MD, Laila Viana, MD, Lucas Fahham, BD, Camila Pepe, BD, Jose Medina-Pestana, MD 
Value in Health Regional Issues 
Volume 14, Pages (December 2017)
DOI: /j.vhri
Copyright © Terms and Conditions

2. Fig. 1
Model structure of health-related events in renal transplant recipients receiving immunosuppressive therapy.
Value in Health Regional Issues  , DOI: ( /j.vhri )
Copyright © Terms and Conditions

3. Fig. 2
Incremental cost effective ratios for selected outcomes: 1. Life-years gained; 2.Graft dysfunction; Full and empty symbols correspond to r-ATG/EVR treatment or BAS/EVR regimens compared to BAS/MPS, respectively.
Value in Health Regional Issues  , DOI: ( /j.vhri )
Copyright © Terms and Conditions

4. Fig. 3
Probabilistic sensitivity analysis: Scatter-plot and 95% Confidence Ellipsoid between incremental cost and incremental effectiveness for selected clinical outcomes (1,000 iterations): CMV infection/ disease: (A) r-ATG/EVR vs. BAS/MPS; (B) BAS/EVR vs. BAS/MPS; Graft loss: (C) r-ATG/EVR vs. BAS/MPS; (D) BAS/EVR vs. BAS/MPS; Graft dysfunction: (E) ATG/EVR vs. BAS/MPS.
Value in Health Regional Issues  , DOI: ( /j.vhri )
Copyright © Terms and Conditions